Literature DB >> 24026246

Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy.

Francois Berthoux1, Christophe Mariat, Nicolas Maillard.   

Abstract

BACKGROUND: The absolute renal risk (ARR) of dialysis/death in IgA nephropathy (IgAN) was based on three major, independent equipotent risk factors: hypertension, proteinuria ≥1 g/day and severe pathological score at diagnosis. We studied, in our prospective regional cohort of IgAN, the impact of body mass index (BMI) on the ultimate outcome in light of this ARR concept.
METHODS: We had information on 331 IgAN patients (233 men). At diagnosis, the BMI was normal (<25 kg/m(2)) in 195 and elevated (≥25) in 136 (44.1%) with 102 overweight (25-29.9) and 34 obese (≥35) defining two groups, normal BMI and elevated BMI, subsequently compared.
RESULTS: At diagnosis, in the overweight/obese group, hypertension and proteinuria ≥1 g/day were more frequent (respectively, P < 0.0001 and P = 0.0006) and the mean global optical score was increased (P = 0.002). This resulted in a worse ARR scoring distribution (P < 0.0001). In addition, these patients with an elevated BMI were ∼10 years older (P < 0.0001), including more obese women and with an eGFR already lower (P = 0.0003). At last follow-up, in the overweight/obese group, progression remained worse with greater prevalence of CKD-3+ (43.4 versus 21.0%; P < 0.0001) and dialysis/death events (21.3 versus 13.9%). Kaplan-Meier survival and Cox regression analyses demonstrated that ARR remained a powerful independent risk factor for prediction of events, but not BMI.
CONCLUSIONS: IgAN patients with an elevated BMI at diagnosis had a significantly worse presentation and worse final outcome. Overweight/obesity increased hypertension frequency, proteinuria level and some renal lesions all of which translate into a worse ARR for prediction of CKD-3+ or dialysis alone or dialysis/death, with no apparent direct effect of BMI per se.

Entities:  

Keywords:  body mass index; disease progression; overweight/obesity; primary IgA nephropathy; risk factors

Mesh:

Year:  2013        PMID: 24026246     DOI: 10.1093/ndt/gft286

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  21 in total

Review 1.  Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome.

Authors:  Jordana B Cohen; Debbie L Cohen
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

Review 2.  IgA Nephropathy.

Authors:  Jennifer C Rodrigues; Mark Haas; Heather N Reich
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 8.237

3.  Proteinuria rebound in IgA nephropathy associated with obesity-related glomerulopathy.

Authors:  Hiro Matsukura; Masako Sakakibara; Izumi Sakamoto; Miho Tatematsu
Journal:  CEN Case Rep       Date:  2015-12-11

Review 4.  Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients.

Authors:  Rosanna Coppo
Journal:  J Nephrol       Date:  2016-11-04       Impact factor: 3.902

5.  Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.

Authors:  Sean J Barbour; Rosanna Coppo; Hong Zhang; Zhi-Hong Liu; Yusuke Suzuki; Keiichi Matsuzaki; Ritsuko Katafuchi; Lee Er; Gabriela Espino-Hernandez; S Joseph Kim; Heather N Reich; John Feehally; Daniel C Cattran
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

6.  Impact of body mass index on primary immunoglobulin A nephropathy prognosis: a systematic review and meta-analysis.

Authors:  Qin Wang; Jian-Jiang Zhang; Wen-Jie Dou; Hui-Qin Zeng; Pei-Pei Shi; Jing Wu
Journal:  Int Urol Nephrol       Date:  2021-08-12       Impact factor: 2.370

Review 7.  Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.

Authors:  Vivette D D'Agati; Avry Chagnac; Aiko P J de Vries; Moshe Levi; Esteban Porrini; Michal Herman-Edelstein; Manuel Praga
Journal:  Nat Rev Nephrol       Date:  2016-06-06       Impact factor: 28.314

8.  Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study.

Authors:  Jordana B Cohen; Alisa J Stephens-Shields; Michelle R Denburg; Amanda H Anderson; Raymond R Townsend; Peter P Reese
Journal:  Am J Nephrol       Date:  2016-05-28       Impact factor: 3.754

Review 9.  Management of Obesity in Adults with CKD.

Authors:  Allon N Friedman; Lee M Kaplan; Carel W le Roux; Philip R Schauer
Journal:  J Am Soc Nephrol       Date:  2021-02-18       Impact factor: 10.121

Review 10.  Strategies to Treat Obesity in Patients With CKD.

Authors:  Kiran Chintam; Alex R Chang
Journal:  Am J Kidney Dis       Date:  2020-10-16       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.